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As the term indicates, capillary fragility means, clinically, capillary ruptures
with visible hemorrhages in tissues. The factors associated with capillary
fragility are the pressure of blood in the vessels, the character of the blood itself
such as platelet and coagulation defects, and finally the character of the capillary
wall, morphologically and functionally. Since many of the widespread derma-
toses do involve the superficial vascular plexuses in the skin, fragility of these
vessels should have some influence on the character and course of the develop-
ment of these dermatoses. In some instances, the results of these tissue hemor-
rhages are obvious, in others the capillary fragility may be only potential and
may be even transient. In dermatology, the study of the phenomenon of capil-
lary fragility itself is much more interesting than the study of attempts of those
forms of therapy which are supposedly specific for this fragility state. Capillary
fragility can be diagnosed by inspection, of course, when severe, but can not be
ruled out without detailed examinations.
In general, the detailed ideal examination for capillary fragility may be sum-
marized as follows:
History
1. appearance of capillary ruptures
2. hypertension
3. diabetes
4. blood dyscrasias
5. other diseases as sepsis, allergies, intoxications, etc.
Physical examination
1. complete physical examination with special emphasis on vascular disturbances
a. evidence of capillary ruptures in skin, mucous membranes and fundi
b. degree of sclerosis of the palpable vessels
a. blood pressure readings
d. extent and types of telangiectasia
e. extent and degree of varicosities
f. venous pressure determinations where indicated
Laboratory data
1. complete blood count including platelets, bleeding and clotting times and clot re-
traction
2. prothrombin
3. vitamin C levels in blood and urine
1 The Hesperidin and Hesperidin Methyl Chalcone were supplied by the Department
of Medicine of the Abbott Laboratories, North Chicago, Illinois.
Read before the sixth Annual Meeting of the Society for Investigative Dermatology,
Chicago, Illinois, June 13, 1944.
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4. serum calcium
5. infra-red photographs where indicated
Positive pressure tests for capillary fragility
1. blood pressure cuff test—arm (1)
2. blood pressure cuff or tourniquet test—leg
3. "flicking" test of Jones and Tocantins (2)
4. Warkany pressure test (3)
This detailed type of examination is limited chiefly to the hospital patient.
In the out-patient dispensary, the physical examination, the blood pressure ci4ff
test or the completely variable "flicking" test are used as methods of evaluating
the degree of capillary fragility.
Tests for capillary fragility have been studied ever since Koch's (4) work in 1890 with
purpura in children and Rumpel (5) (1909) and Leede's (6) (1911) work on skin hemorrhages
in scarlet fever. The positive capillary fragility test produces its result by an increase in
intracapillary pressure caused by the interference with the venous return. This disturb-
ance results in relatively gross capillary damage. Perhaps in dermatology, the study of
less severe degrees of capillary permeability, such as the passage of fluid through the capil-
lary wall, would be of more interest and concern (7).
The Wright modification of the Gothuin Technic as outlined by Beaser, Rudy and Selig-
man (1) seems to be the best standardized pressure test technic for capillary fragility avail-
able today. In regard to this positive pressure type of test, the length of the time interval
and also the discomfort of the fifteen minutes of maintained pressure midway between
the systolic and diastolic pressure, is an objection to the widespread practical use of this
method. In the out-patient dispensary, especially, this interval can be used for securing
more history details from the patient and for the remainder of the physical examination.
Another objection to this modified Gothlin technic as indicated by Beaser, Rudy and Selig-
man (1), is the fact that a proper level of pressure has not been determined as yet for the
patient with hypertension. Moreover, we have found that the distribution of petechiae
produced by this pressure test may be diffuse or spotty and if we confined ourselves to an
area 4 cm. below the elbow, this area may be entirely free of petechiae. Therefore, we have
moved this 2.5 cm. circle into a fairly uniform area of petechiae, usually directly in the
antecubital fossa and we have still considered 20 as the upper limit of normal. We believe
also that the character of the petechiae should be described in addition to the number as:
1. to size and shape
a. small
b. large
(1) circular
(2) irregular
(3) linear
c. mixed
2. to color intensity
a. faint
b. intense
(1) reddish
(2) bluish
The visualization of the petechiae may be facilitated by the use of a strong light, a
magnifying glass and some (two to four) minutes after the pressure has been released (end
point of capillary hemorrhaging?) by the application of oil or xylol on the skin to visualize
the deeper hemorrhages and gentle pressure on the skin to produce some anemia. Griffith
and Lindauar (8) have recently proposed a petechial index after Gothlin. A normal index
is eight or less. To answer some of the objections to the time required for this technic
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they indicate that second stage of fifteen minutes may be omitted under certain conditions.
Griffith and Lindauer state "that a normal test is not significant if done within three weeks
of a previous test."
With obvious reasons, the upper extremities have been used as the commonest
sites for capillary fragility testing. Yet these should not be the only ones con-
sidered. In dermatology, attention is frequently directed to the lower extremi-
ties and some form of pressure tests should be done here also. These tests are
much more difficult to do on the legs and are frequently unsatisfactory. Per-
haps a larger cuff should be used on the lower extremity. We have tried the
tourniquet test, pressure cuff both about the thigh and below the knee and the
"flicking" test. Differences in readings between the arms and legs will be men-
tioned in the discussions of the cases.
The modified "flicking" test and the Warkany pressure test are practical unstandardized
methods for the rapid detection chiefly of marked capillary fragility. For the "capillary
ifick test" modified after Jones and Tocantins (2), a tourniquet is put around the arm for
five minutes and after four minutes of tourniquet pressure, the distended veins of the elbow
are flicked twice by the thumb and middle finger of the examiner. A control flicking may
be done just above the tourniquet on the arm. After the release of the tourniquet, the
petechiae in the elbow area are counted. Zero to ten petechiae are assumed to be "nor-
mal." With this number, this too sensitive and unstandardized test will be positive in
approximately twenty per cent of normal individuals. With moderate and severe states
of capillary fragility the skin not over veins will show petechiae in significant numbers.
The Warkany (3) pressure test, is especially valuable for children. In this test the distant
portion of the little finger is squeezed for two minutes by the thumb and forefinger of the
examiner and the number of petechiae visible on the flexor surface of the tip of the little
finger is counted. This test is similar to Hecht's "pinching" test on the trunk, reported
in 1907. It should be emphasized again that potential capillary fragility may exist, of
course, in the absence of visible evidence of capillary ruptures. This potential phase can
be elicited by the pressure tests for capillary fragility.
In conclusion, a reliable and practical and standardized test for capillary
fragility is still needed, especially for the detection of early changes from normal.
The severe case is obvious. When a test is used, its details should be described
and its repetition especially after an "interval" is desirable.
The patients whom we studied were divided into two main groups, namely,
those with obvious and those with potential capillary fragility. Because of our
special interest in the stasis syndrome, such cases were considered in a separate
class although they belong to both groups of capillary fragility. In addition,
a small experimental group of patients with contact dermatitis and with contact
stomatitis were treated to determine the preventive effect of hesperidin methyl
chalcone on the positive patch or positive mucous membrane contact test reac-
tions. Hesperidin methyl chalcone was used also intravenously in an experi-
mental study of its effect on reactions to massive arsenotherapy at the Intensive
Therapy Center of the Department of Dermatology at the Cincinnati General
Hospital.
The reason for our interest in vitamin P was our usual lack of success with
vitamin C therapy in dermatological patients. This included the use of large
doses of ascorbic acid intravenously. Save for the occasional case of clinical
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and subclinical scurvy patients which we have seen, and one excellent result in
Schamberg's disease (C level in blood not lowered) in addition to elastic bandages
on the legs, and some questionable results in a patient with scleropoikioderma,
the remainder of our therapeutic trials in dermatOlogical patients with capillary
fragility states have been a failure. In another case of Schamberg's disease with
decreased capillary fragility tests in the legs also, a deliberate attempt was made
to try to prove this increased capillary fragility on the legs by means of treat-
ment with positive and negative pressure glass boot (Paveaux) used for peripheral
vascular disease. After several treatments with this, the discrete lesions of
Schamberg's Disease on the legs were transferred into a solid brown hemosideric
pigmentation "stocking" extending from just below the ankles to the edge of
the cuff of the apparatus. No vitamin C was given to this patient. After this
experience he left the clinic. Blood vitamin C levels were of no help either
in the diagnosis of the capillary fragility state or in response to vitamin C therapy.
The blood vitamin C level was of help only in ruling out scurvy, that is scurvy
is not present with blood levels above 0.6. Scarborough (9) has indicated that
"a deficiency of ascorbic acid is not necessarily complicated by low capillary
resistance." In patients with reactions to arsenic in the arsenotherapy of
syphilis, especially with dermatitis, it was difficult to determine the role of
vitamin C since many diverse therapies were always tried at the same time.
There has been much controversy concerning the concept of vitamin P.
Hazel (10) claims "that is highly questionable whether such a vitamin exists."
Although yellow plant pigments, the flavones were studied since 1931 by Aka-
matsu and in 1935 by Fukuda, there was no great interest until the reports by
Armento and Szent-Gyorgi in 1936 of the "vitamin-like action of two crude
flavone preparations from lemon peel, citrin and eriodiction, the treatment of
abnormal capillary permeability and fragility (11)."
Conflicting reports were then published on the value of this group. In 1938
Szent-Gyorgi (12) reported that he could not confirm his results of two years
previously. Detrick, Dunn, McNamara and Hubbard (13) found that in vita-
min C deficient guinea pigs, citrin neither decreased the hemorrhagic condition
of scurvy nor prolonged the life of the animal. Although the original work
done by Szent-Gyorgi and his associates was with extracts of Hungarian red
pepper and lemon juice (12), the substances used in present day experiments
are made usually from oranges and lemons. Extracts from lemon peel include
hesperidin glucoside and eriodicytol glucoside, but orange peel contains chiefly
hesperidin glucoside and no eriodicytol (11). It is important to remember that
various general factors determine type of extract secured. These factors include
ripening of the fruit and the type isolation technic adopted. Although there is
not complete agreement on this subject (14), for the purpose of this report it
may be assumed that the forms of hesperidin include:
1. crude—water soluble yellow pigment, inert pectinous material;
2. chalcone—supposedly the biologic active component, made from hes-
peridin by treatment with alkali, unstable in storage and heating in neutral
water;
CAPILLARY FRAGILITY STATES 135
3. methyl chalcone—made by methylation of the hydroxyl group
a. readily soluble in water
b. causes depression of blood pressure
c. has an effect in capillary fragility.
Rudy, Beaser and Seligman (15) have summarized critically the reports on
the use of vitamin P clinically and indicate the wide variety of patients for whom
these compounds have been tried. Moreover, these authors themselves ob-
tained negative results with both orally and parenterally administered vitamin
P in diabetic patients with increased capillary fragility and also in two patienta
with thrombopenic purpura and one case of rheumatoid arthritis. The time
interval oL the capillary fragility test after the intravenous compound was not
given. Scarborough (0) believes that some forms of purpura may be on a nutri-
tional basis. These hemorrhages, in ascorbic acid deficiency, may be large and
be found in the subcutaneous tissue and in muscle. The hemorrhages of de-
creased capillary resistance are fine in type and are circumpilar. He further
believes, that vitamin P deficiency is characterized by a decreased capillary
resistance, feelings of lassitude and easily induced fatigue, pains in the shoulders
and legs and no hematological abnormality. Goldfarb (16, 17) has had some
success in the treatment of psoriasis with citrin lemonade. Experiences with
vitamin P in arsenotherapy will be detailed later.
In seventeen patients with obvious capillary fragility, crude hesperidin and
hesperidin methyl chalcone in adequate doses were seemingly without any
lasting clinical effect as regards capillary fragility. In the patients in whom
clinical improvement was reported there were other and more likely factors
which could explain this improvement. In these patients, likewise, the pres-
sure tests became normal as the condition improved. In three patients in this
group, and in three patients from medical services, the methyl chalcone was used
intravenously. Mild reactions from the hesperidin were noted in only one case
even when it was used intravenously both in this and in our other series of cases.
No immediate blood pressure reductions were observed. In all the intravenous
cases the capillary fragility tests were repeated within ten to fifteei minutes
after the intravenous injections and in four patients significant decreases in
capillary fragility were obtained and in several patients this decrease was re-
ported to have been obtained repeatedly. In Case 12 (the Kaposis (1)) some-
times a slight decrease was obtained. In Case 7 there was a slight increase
which was not maintained after four doses were given. There was no sig-
nificant clinical improvement in any of the patients.
Additional clinical notes are worthy of recording on some of the cases.
In case 1, epidermolysis bullosa with petechiae, there has been little comment in the
literature on capillary fragility in this acquired form although of course, hemorrhagic
bullae have been noted before.
It is interesting that in four of our patients, all women, the capillary fragility was asso-
ciated, at least in time relationship, with endocrine disturbances. It is probable also
that the clinical improvement was due to the endocrine therapy.
Five cases of lichen planus were examined for capillary fragility, two of these patients
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had clinical capillary fragility and one had potential capillary fragility. All three patients
were of middle age and without any known factors for this capillary fragility. A youth
with generalized severe lichen planus had no capillary fragility.
Case 10 of this series had had allergic purpura (bacterial allergy?) for years. After the
use of nose drops containing sulfathiazole, a focal eczematoid sulfathiazole eruption de-
veloped on an old healed burn area previously treated with sulfathiazole ointment. Asso-
ciated with this was a very severe urticaria and angioneurotic oedema. Negative passive
transfer tests, both intradermal and patch, were obtained with sulfathiazole solution (not
incubated in serum.) A generalized lichen planus developed in this patient and has re-
curred since. No isomorphic response would develop from the petechiae but the lichen
planus lesions were occasionally purpuric. Patch tests to sulfathiazole were of the eczema-
toid type and did not change into lichen planus types even when done during flare up epi-
sodes of lichen planus. Bacterial skin tests likewise did not become purpuric although
at times they were severe.
Case 11 revealed a unilateral purpuric lichen planus with confirmation of this diagnosis
obtained on biopsy with the Prussian Blue reaction. Here too, the isomorphic response,
did not occur from the pressure tests, nor from scratching the skin. Only deep smooth
brownish pigmentation followed the scratching but there were no lichen planus lesions.
At present, this patient could be considered as unilateral localized purpuric and hemosideric
lichen planus. She was treated over a period of approximately four months and after this
time showed no striking clinical response, the purpuric lichen planus gradually becoming
browner. The capillary fragility tests actually showed some increased fragility with 13
as her pretreatment level and 41 as final post treatment test. Earlier after more than two
months of therapy with the crude hesperidin her fragility tests were 28 and 27.
Case 12 was an elderly man without hypertension who developed an indurated bluish
tumor of the scalp following trauma. This tumor had persisted for six months and was
associated with repeated episodes of soft tissue hemorrhage. In spite of the scalp location,
hemorrhagic sarcoma of Kaposi seemed likely because of the angiomatous and telangiectatic
areas about this tumor and gradual spread of the tumor and the good general health of the
patient. This diagnosis was confirmed by biopsy. His laboratory tests as the charts
indicates were abnormal and likewise his capillary fragility. There was no response to
small doses of oral methyl chalcone. Occasionally there was some reduction in the capil-
lary fragility test when the methyl chalcone was given intravenously, once together with
calcium and ascorbic acid, but this reduction was not constant. Vitamin K was used also.
The hemorrhage and discoloration faded somewhat but the tumor was unaffected. X-ray
therapy was started on the tumor. The tumor then became infected secondarily and re-
quired incision and drainage. In another patient with extensive hemorrhagic sarcoma of
Kaposi including upper and lower extremities, an elderly Italian man, capillary fragility
tests were negative both on the arm and leg. This was surprising on the leg because of the
purpuric ciaracter of some of the areas. These tests were done before and after roentgen
therapy Certainly in this patient because of the actual presence of the lesions in both
extremities and associated lymphoedema there must have been increased intracapillary
pressure. No venous pressure studies were done.
Intravenous hesperidin was used on the medical service on several patients. An el-
derly lady (patient of Dr. Ogura) with biliary cirrhosis and thrombocytopenic purpura
was given intravenous hesperidin. Shortly after this, the previously strongly posifive
fragility test became negative but soon became strongly positive again. These tests were
all done when the patient was in shock. Another patient on the medical service (patient
of Dr. Richard Vilter) with Henoch's purpura showed transient but definite changes in the
capillary fragility tests immediately after intravenous hesperidin.
Three cases of nutritional deficiencies with purpura were observed and all these occurred
during the course of reduction diets. Although no blood C levels were obtained the pa-
tients were clinically scurvy. One showed improvement, including the capillary fragility
test, when an adequate diet and hesperidin were used (Case A). One patient showed a
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transient improvement in the capillary fragility test after 200 mgs. of the chalcone were
given intravenously (case 16). Immediately following the injection this patient com-
plained of a chill and headache. This disappeared quickly. The patient was not given
vitamin C. He left the hospital before additional studies could be secured and since no
vitamin C levels were obtained on him, the diagnosis of scurvy could not be made definitely
in his case.
In a dermatological patient the state of potential fragility can be suspected
(in the absence of petechiae) by the bluish cast to some of the lesions, especially
on the lower extremities and by a linear reddish streaking of some of the excoria-
tions. Even without such hints and without the systemic background for the
lowering of capillary resistance such as hypertension, diabetes, blood dyscrasia,
etc. one can frequently detect such "potential" capillary changes by the positive
pressure test. This is shown in table 2 by the appearance of capillary fragility
in diverse conditions including even generalized contact dermatitis. In one
patient seen some years ago with hemorrhagic poison ivy dermatitis, the strongly
positive tourniquet test, done in those days, became negative after the dermatitis
subsided. Three cases of rosacea without hypertension showed capillary fra-
gility, two mild and one severe. The severe fragility was found in a young
woman. To date these fragility states are still present one not affected by oral
hesperidin, the other not given hesperidin. Capillary fragility was found in
four eases of spider naevi, one of these in a child. Two of the cases were con-
genital in origin, one was associated with pregnancy and one with rosacea. Six
cases of severe urticaria were studied in sufficient detail. Two were acute and
four were of the chronic type with the etiology undetermined. Two of the acute
cases were psychogenic in type. One of these, a middle aged woman with hyper-
tension and moderately severe coronary disease, showed approximately 100
petechiae on capillary fragility testing with many of these hemorrhages huge,
fluffy and bluish, in type. With the spontaneous disappearance of the urticaria
under sedation, the capillary fragility test was reduced to only 20—30 and of the
fine pale type. She received no hesperidin. Rapaport and Klein (12) have
noted increased fragility in allergic children. They reported improvement with
vitamin P.
The value of the leg and arm capillary fragility tests was demonstrated in a
young girl with erythema nodosum, probably streptococcic in origin. The test
was negative on the arm during the early phase of the disease and moderately
positive on the legs, 10—15 with the tourniquet test. There was pain and in-
creased bluishness of the lesions on the legs tested. With the subsidence of the
erythema nodôsum, the faint bluish areas were not influenced by the test and a
tourniquet test and a Wright modification of the Gothlin test on the leg showed
no petechiae at all. A patient with erysipeloide epidermophytide with large
varicosities had negative capillary fragility tests on the forearm and negative
tourniquet tests on the affected and unaffected leg.
When an individual with a previous and established capillary fragility de-
velops a generalized dermatitis some of the lesions may have purpuric qualities
not only on the lower extremities but even on the upper arm. Scratch marks
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may be outlined with linear petechial hemorrhages. One woman whose history
indicated a capillary fragility of some years duration developed localized sclero-
derma of the trunk and later a contact dermatitis. The localized soleroderma
showed with regard to the vascular component, extensive telangiectatic markings
without petechiae. Pressure with the fingers on the scleroderma area produced
no petechiae. Many of the contact dermatitis papules and vesicles were pur-
puric. Blood pressure cuff test on one arm made all the lesions of contact
dermatitis below the area of pressure purpuric and produced many petechiae.
This capifiary fragility had no influence on the duration of the dermatitis and
was present after the dermatitis cleared. Another patient with marked capil-
lary fragility developed maculo-papular syphilides, none purpuric. There were
no abnormal hematological findings. Pressure cuff produced purpuric changes
only in some of the lesions on the tested arm. Alter the syphilis improved the
capillary fragility was not marked. An infant with unusually severe hemor-
rhages from a small granuloma pyogenicum of the face was found to have a
capillary fragility. Examination revealed a hypoprothrombinemia. When
one does positive pressure tests on individuals with dermatitis of the extremities
as indicated above, no definite patterns of petechial or purpuric changes or
mottling can be established. Certain irregular areas assume darker hues, some
of the lesions may present halos of peculiar light cherry red color. On the legs
circumpilar mottlings may be scattered below the tourniquet. Superficial
lesions of stasis syndrome become bluish red. Here too no definite patterns
can be made out. it is possible that the variability of the patterns on the ex-
tremities is due to location of the venule or capillary (or other vascular com-
ponent) involved, the depth in the skin of this vessel, the caliber of this vessel,
the degree of intravenous and intracapilary pressure and the degree of per-
meability of the vessel wall.
Detailed testing of two severe bullous dermatitis herpetiformis cases in children
and one mild ease in an adult showed no capillary fragility and no hemorrhage
into the bullae below the pressure area.
Stasis syndrome has been a long time study of one of us (L. G.) with special
emphasis on the prophylaxis and the therapy of the early phases. Together
with Dr. Louis G. Herrmann of the Department of Surgery and Director of the
Peripheral Vascular Disease Service of the Cincinnati General Hospital a de-
tailed study of the stasis syndrome has been initiated. This study will include
in addition to the general complete study of the patient, the analysis of the local
vascular dynamics, cutaneous physiology and pathology, bacteriologic and
mycologic examinations and immunologic responses and also soft tissue x-ray
studies of the degree and extent of dermal and subcutaneous fibrosis. This
latter study is included because we have felt that severe drmai and subcutaneous
fibrosis "honeycomb type" means a poor prognosis as regards the possibility of
re-establishing good circulation in the lower leg.
For an arbitrary classification of the clinical picture of stasis syndrome, we
are dividing it into four phases. In any one of these phases dilated veins may
be present in varying degree or absent not only on inspection and thorough
testing but even through infra-red pictures.
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Phase I—petechiae, zero to minimal cutaneous reactions
Phase II—petechiae, hemosiderosis, erythemato-squamous reaction
Phase III—petechiae, hemosiderosis, erythemato-squamous and eczematoid
reactions, edema, induration
Phase IV —ulcer, edema, dermatitis
We are reporting a portion of our study on Phase I. This work includes ob-
servation of eleven patients for periods varying from one and one-hall to two
and one-half months at the Chronic Disease Hospital. The patients were all
up-patients and had the Wright Modification of the Gothlin technic done on
the upper extremities and the tourniquet test (fifteen minutes) done on the
lower extremities. The tests were repeated at intervals. No local therapies
were used.
In this group of patients, all in the upper age groups, fragility was increased
in six, but only in three without hypertension. Tests on the legs were uniformly
unsuccessful but did not, at least seem to aggravate Phase I of the stasis syn-
FIG. 1. CLINICAL PHASES OF THE STASIS SYNDROME
drome. In spite of the long maintained dosage schedule, save for the few cases
treated only with intravenous hesperidin methyl chalcone, clinical improvement
was not striking. In spite of changes in the capillary fragility tests, many of
them not significant, none of the lesions were aggravated under hesperidin
therapy. The relationship between blood pressure level and number of petechiac
was shown clearly and again ifiustrates the need for a "proper level" for the
hypertensive patient. In common with our experiences with other types of
cases, four of the six patients given intravenous hesperidin methyl chalcone
showed some transient decrease in the capillary fragility test, two showed an
actual increase. No depression of blood pressure was noted in any of the cases
in whom the intravenous therapy was given. In one patient with a blood
vitamin C level of 0.53, 5.1 gm. of ascorbic produced no improvement clinically
nor in the capillary fragility test. Case 2 was also given ascorbic acid without
improvement. In another patient, not of the Chronic Hospital series, large
doses of vitamin C given over a period of three months did not affect the in-
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ECZCIII&TOID DERMATITIS. CCZCMATOID DUMAmp%
IDES IDES
PflECHIAt + ++ + OR It + OR ++
PEkIOSIDEROSIS + OR 0 + OR ++ ++ ++
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TABLE 3
Capillary fragility studies in stasis syndrome (11 patients)
BLOOD POSITIVE PRESSURE TESTS
PRES- — .__. — — — —
SURE TYPE EESPERWSN AND RESULTS ANDRAISE AGE LEVEL TOTAL DOSAGE REMARKS
FOR
TEST
1. G. H 78 125 12 2 36 0 17 3 Crude 104.0gm. Some improve-
chalcone, 420 ment
mgm.
2. G. Z 66 100 13 2 24 0 39 0 Crude 170.0 gm. No improve-
30 1 15 1 M. chalcone, ment, blood
4.2 gm. C. 0.37, also no
improvement
under 4.2 gin.
ascorbic acid
3; T. N 71 105 49 4 24 2 58 1 Crude 128.0 gm. Some improve.
25 1 19 0 M. chalcone, merit15 0 Somgm.I.V.,
5 doses
4. J. M 76 85 8 4 36 3 22 1 Crude 90.0 gm. No improve-20 0 30 0 M. chalcone, ment12 0 50 mgm. I.V.,
S doses
5. W. T 70 125 62 2 15 1 28 2 Crude 125.0 gm. No improve.
22 1 32 0 M. chalcone, merit11 0 50 mgm. LV.,
5 doses
6. L. T 54 140 57 0 40 0 24 2 M. chalcone 50 No improve-
mgm. I.V., 5 merit, vitamin
doses C 0.53
7. W. M 71 105 12 1 23 0 36 2 M. chalcone 50 No improve-
mgm. I.V., 5 merit
doses
8. J. C 77 110 20 1 50 0 18 1 M. chalcone 50 No improve.
mgm. IV., 5 merit
doses
9. L. T 54 135 24 2 21 0 23 0 No hesperidin No improve.
merit, given
5.1 gm. ascor-
bic acid
10. G. D 65 105 33 1 14 1 Crude 30.0 gm. Some improve-
M. chalcone, merit
2.41 gm.
11. W. W 78 150 61 2 23 1 Crude 39.0 gm. No improve.
M. chalcone, ment
2.6 gm.
Positive pressure tests: arm, Wright modification of Gothlin technic; leg, tourniquet,
fifteen minutes.
Tests during therapy, usually when changed to another type of hesperidin.
Tests after intravenous hesperidin methyl chalcone, tests done after first and then after
last injection.
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creased capillary fragility nor the petechial and purpuric aspects, in Phases 11-
111 of the stasis syndrome.
With the pressure technics now available, we have not proved intrinsic capil-
lary fragility even in the lower extremity in Phase I although clinically there is
evidence of damage to vessel wall.
However, it seems likely that the capillary fragility when it is present in Phase
I is more often a localized process and due in part to structural changes in the
vessel wall as part of the vascular scierosing process and also to the increased
hydrostatic pressures of the venous columns. Systemic conditions by producing
circulating noxious agents may initiate or aggravate vessel wall damage in the
lower extremities. Although only few vitamin C levels were done, vitamin C
therapy previously had not been found to be of much value in the systemic
therapy of this phase. The only practical recommendations available at present
are first, measures to improve the circulation by means of rest, elevation and
supportive bandages and the avoidance of increased local heat, and second,
measures to prevent irritation sensitization and infection of the skin in this area
by means of proper detergents especially in cold weather, bland oils and creams,
early therapy for minor lesions and as far as possible, prevention of local trauma.
The general therapy includes the treatment of any systemic condition present,
especially if this condition adds to increased intra-vascular pressure or to actual
damage of vessel wall.
From work with rabbits, Goldstein, Stolman and Goldfarb (20) concluded
that when methyl chalcone was given together with mapharsen, more animals
survived than when mapharsen was given alone. They believed further that
the methyl chalcone did not inhibit the spirocheticidal activity of mapharsen
in vitro but it actually had an independent spirocheticidal activity on the
spirochaete. The brain damage in arsenical encephalitis they interpreted as
due to increased permeability of the capillary wall. Gorrie (21) reported an
arsenical purpura hemorrhagica with severe thrombopenia, treated with hes-
peridin and ascorbic acid.
In a small series of nine patients receiving the five day continuous intravenous
drip with only 200 mgm. mapharsen daily, preceded by two injections of bismuth,
the effect of intravenous hesperidin methyl chalcone was studied. The Wright
Modification of Gothlin technic was done before therapy started, during therapy
and after therapy was completed. During and after the intravenous drip the
tests were not done on the arm in use or immediately after use. No increased
capillary fragility was detected in eight of the nine patients at any time. This
small series included also one fatal case of hemorrhagic encephalitis starting
abruptly on the sixth day after a completely uneventful five day period of con-
tinuous drip.
In only one of the patients could increased fragility be demonstrated and that
only on the sixth day and seventh day. This patient developed thrombo-
phlebitis appearing after a transient type of phlebitis developed in the opposite
arm and forearm. No capillary fragility tests were done during the acute phase
of the angiospasms but later on the sixth day, this test done on the arm, which
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had a definite thrombophiebitis, showed 40 petechiae although this test had been
negative on the third day of the drip. Hesperidin was given intravenously
to this patient, only one injection of 300 mgm. with some definite reduction
change in the fragility test but this was only transient. In spite of the absence
of decreased capillary fragility in the other patients, intravenous hesperidin
methyl chalcone in doses 50 to 300 mgm. was used in an effort to help the nausea
and emesis and also to attempt to relieve the angiospasms which occurred in
practically every case. The hesperidin was completely without effect. In our
small series, other vitamin compounds were not used. The angiospasms, how-
ever, could be relieved by the use of Spasmalgin as suggested by Weiner (22).
In a patient not of this series, who developed vesicular arsenical dermatitis
with petechiae and with normal hematological findings, the fragility test was
positive, 35. The hesperidin methyl chalcone was given orally, 60 mgm. daily
for a total of 1.0 gm. The petechiae did not disappear and the fragility test
did not change until the arsenical dermatitis cleared.
Hesperidin methyl chalcone was tried in daily doses of 60 mgm. for a period
of two weeks in an individual who was known to be very sensitive to nickel,
and who had had increased capillary fragility only during the course of her nickel
dermatitis. After the end of this time contact tests to nickel sulfate done on
the skin and in the mouth with the technic which we have reported (23) showed
strongly positive reactions in the skin and in the mucous membrane of the lip.
A similar unsuccessful result was obtained in a patient who had a marked hyper-
sensitivity to mercury and who presented linear petechiae in. her excoriations
during the episode of her dermatitis. These petechiae disappeared and her in-
creased capillary fragility was reduced after the dermatitis subsided. The
contact tests to mercury were done on the skin and on the buccal mucous mem-
brane. Hesperidin methyl chalcone, given in the same doses and over the same
time interval, was unsuccessful in preventing positive patch test reactions in
three patients who exhibited no evidences of increased capillary fragility. As-
corbic acid had previously been used in this type of experiment without success.
In general then, so-called vitamin P was of no clinical value to us in the prac-
tical therapy of the capillary fragility state in dermatology. However, there
was an occasional rapid and fugitive and even striking effect on the capillary
fragility test when the hesperidin methyl chalcone was given intravenously.
This may mean that there is some factor in this compound which does affect
capillary permeability. When the chemistry of this compound has been worked
out in greater detail and its preparation standardized, then more uniform results
may be obtained and greater quantities may be employed in clinical trial under
critical analysis.
The therapy of capillary fragility in the dermatological patient may be out-
lined briefly:
1. the general and/or the local treatment of the particular condition under-
lying the capillary fragility.
2. when evidences of vascular damage are found on the lower extremities
efforts should be made to avoid aggravation of the condition by rest and
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elevation of the leg, prevention of irritation and increased heating of the
skin.
3. ascorbic acid may be given in proved ascorbic acid deficiency.
4. calcium may also be used as one of the therapeutic agents of lesser im-
portance.
5. intravenous hesperidin or hesperidin-like preparations should be used only
in purely investigative studies under controlled critical conditions. The
present oral preparations now available are of no value.
Brief note should be made also of the much more important occurrence of
visceral capillary fragility, as for instance cerebral hemorrhage. In the case
reported by Gorrie (21) retinal hemorrhages occurred after the purpura on the
skin cleared. He mentions also that this sequence has been found with cerebral
hemorrhages. The possibility of visceral capillary fragility must always be
considered then in the analysis of the patient with petechiae and purpura and
even with improvement in the state of capillary fragility in the skin.
SUMMARY AND CONCLU5ION5
The study of the capillary fragility state in dermatology reveals this state
to be a rather common one, usually not of great practical interest unless it be
severe or on the lower extremities where it may initiate a stasis syndrome.
Petechial, purpuric or hemosideric manifestations may be added to the cutaneous
picture when capillary fragility complicates dermatitis.
The need for a standardized capillary fragility test is still great especially in
the detection of the early or borderline case. The Wright Modification of the
Gothlin technic appears to be the best standardized test available but this may
be impractical under some circumstances and too sensitive in patients with
hypertension. The unstandardized tourniquet, "flicking" and Warkany pres-
sure tests may also be used. Tests for capillary fragility determinations on the
lower extremities were unsuccessful.
Obvious capillary fragility with actual hemorrhages and potential capillary
fragility, detected by capillary fragility tests, were found in a variety of common
and uncommon dermatological conditions.
A classification of stasis syndrome was given and the prevention and therapy
of the early phases was emphasized.
Crude hesperidin orally and hesperidin methyl chalcone both orally and in-
travenously were found to be of no value in the treatment of these capillary
changes.
In a small series of patients undergoing the intensive arsenotherapy, no de-
creased capillary resistance could be detected save in one patient who developed
a thrombophlebitis. The series also included a fatal case of hemorrhagic en-
cephalitis.
Hesperidin methyl chalcone did not prevent positive contact tests on the skin
and in buccal mucous membrane, of individuals with previous episodes of con-
tact dermatitis and contact stomatitis.
Transient and at times striking decreases in the positive capillary fragility
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test were noted occasionally immediately after the intravenous use of hesperidin
methyl chalcone. This suggests that some hesperidin mixtures may contain
small amounts of a utilizable substance affecting capillary permeability.
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DR. SAMUEL M. PECE: I have been interested in this field for a number of years. We
have shown in a number of publications (Peck, Samuel M., Rosenthal, Nathan, and Erf,
Lowell A. Intradermal venom reaction as new method of determining capillary fragility.
Proc. Soc. Exper. Biol. and Med., 35: 614—616, 1937.) (Peck, Samuel M., Rosenthal, Nathan,
and Erf, Lowell A. The value of the prognostic venom reaction in thrombocytopenic
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purpura. J. A. M. A., 106: 1783—1791 (May 23) 1936.) (Peck, Samuel M., Rosenthal, Na-
than, and Erf, Lowell A. Purpura, classification and treatment, with special reference
to treatment with snake venom. Arch. Dermat. and Syph., 35: 831—864 (May) 1937.)
that the usual methods for testing capillary fragility not only tests changes in the capillary
walls, but changes in the supporting structures around the capillaries. The method for
testing capillary fragility described in the presentation of Doctors Goldman and Corrill,
as in the other methods, depends on the reactions to changes in intracapillary pressures.
We were able to show that in certain purpuric eruptions, the purpura was due more to
changes in the supporting structures around the capillaries than to changes in the capillary
walls themselves. An increase in intracapillary pressure resulted in minute hemorrhages
because of the damage to these supporting structures. By means of the venom test we
were able to obtain a more accurate estimation of changes in the capillary walls themselves
because by this method we were testing the resistance of the endothelial cells to the hemor-
rhagic action of the mocassin venom. The changes in the supporting structures played no
role in this test.
Dii. LEON GOLDMAN: Dr. Peck's discussion brings up the question that there is no tech-
nic. In regard to the suction tests I have agreed, and have discontinued them because
they are so variable. We have adopted the tests recommended by those interested in this
subject in the Department of Internal Medicine.
There are three good reasons for decreased capillary resistance, or increased fragility.
The most common, of course, occurs in people with hyperteusiou. It presents the greatest
obstacle in routine testing in clinical practise. Capillary fragility may he due to an actual
defect of the blood constituents themselves, such as platelet diminution or hemophilia,
and lastly, there is the factor of permeability of the capillary wall, which cannot be studied
in a controlled practical manner at the present time.
We get positive capillary fragility tests in a variety of conditions. The strongest test
we ever had was in an individual who had psychogenic urticaria, and who improved chiefly
on sedation.
